D
Dipen M. Maru
Researcher at University of Texas MD Anderson Cancer Center
Publications - 230
Citations - 15947
Dipen M. Maru is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 55, co-authored 217 publications receiving 12560 citations. Previous affiliations of Dipen M. Maru include Genentech & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
The consensus molecular subtypes of colorectal cancer
Justin Guinney,Rodrigo Dienstmann,Rodrigo Dienstmann,Xingwu Wang,Xingwu Wang,Aurélien de Reyniès,Andreas Schlicker,Charlotte Soneson,Laetitia Marisa,Paul Roepman,Gift Nyamundanda,Paolo Angelino,Brian M. Bot,Jeffrey S. Morris,Iris Simon,Sarah Gerster,Evelyn Fessler,Felipe De Sousa E Melo,Edoardo Missiaglia,Hena R. Ramay,David Barras,Krisztian Homicsko,Dipen M. Maru,Ganiraju C. Manyam,Bradley M. Broom,Valérie Boige,Beatriz Perez-Villamil,Ted Laderas,Ramon Salazar,Joe W. Gray,Douglas Hanahan,Josep Tabernero,René Bernards,Stephen H. Friend,Pierre Laurent-Puig,Jan Paul Medema,Anguraj Sadanandam,Lodewyk F. A. Wessels,Mauro Delorenzi,Mauro Delorenzi,Scott Kopetz,Louis Vermeulen,Sabine Tejpar +42 more
TL;DR: An international consortium dedicated to large-scale data sharing and analytics across expert groups is formed, showing marked interconnectivity between six independent classification systems coalescing into four consensus molecular subtypes (CMSs) with distinguishing features.
Journal ArticleDOI
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
Ben Tran,Scott Kopetz,Jeanne Tie,Peter Gibbs,Zhi-Qin Jiang,Christopher H. Lieu,Atin Agarwal,Dipen M. Maru,Oliver M. Sieber,Jayesh Desai +9 more
TL;DR: This study investigates whether BRAF mutant CRC is further defined by a distinct pattern of metastatic spread and explores the impact of BRAF mutation and microsatellite instability (MSI) on prognosis in metastatic CRC.
Journal ArticleDOI
Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases
Dan G. Blazer,Yoji Kishi,Dipen M. Maru,Scott Kopetz,Yun Shin Chun,Michael J. Overman,David R. Fogelman,Cathy Eng,David Z. Chang,Huamin Wang,Daria Zorzi,Dario Ribero,Lee M. Ellis,Katrina Y. Glover,Robert A. Wolff,Steven A. Curley,Eddie K. Abdalla,Jean Nicolas Vauthey +17 more
TL;DR: Evaluated patients who underwent preoperative irinotecan- or oxaliplatin-based chemotherapy, followed by resection of colorectal liver metastases found that degree of pathologic response represents a new outcome end point for prognosis after resections of CLM.
Journal ArticleDOI
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
Scott Kopetz,Jayesh Desai,Emily Chan,J. R. Hecht,Peter J. O'Dwyer,Dipen M. Maru,Van K. Morris,Filip Janku,Arvind Dasari,Woonbook Chung,Jean Pierre J. Issa,Peter Gibbs,Peter Gibbs,Brian P. James,Garth Powis,K. B. Nolop,Suman Bhattacharya,Leonard B. Saltz +17 more
TL;DR: Single-agent vemurafenib did not show meaningful clinical activity in patients with BRAF V600E mutant CRC, and combination strategies are now under development and may be informed by the presence of intratumor heterogeneity of KRAS and NRAS mutations.
Journal ArticleDOI
Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases
Yun Shin Chun,Jean Nicolas Vauthey,Piyaporn Boonsirikamchai,Dipen M. Maru,Scott Kopetz,Martin Palavecino,Steven A. Curley,Eddie K. Abdalla,Harmeet Kaur,Chusilp Charnsangavej,Evelyne M. Loyer +10 more
TL;DR: In this article, the authors evaluated CT images for morphologic changes, based on metastases changing from heterogeneous masses with ill-defined margins into homogeneous hypoattenuating lesions with sharp borders.